{
    "clinical_study": {
        "@rank": "143043", 
        "arm_group": [
            {
                "arm_group_label": "Blisibimod", 
                "arm_group_type": "Experimental", 
                "description": "Blisibimod administered subcutaneously"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered subcutaneously"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod\n      administration in addition to standard therapy in patients with biopsy proven IgA\n      Nephropathy with persistent proteinuria of between 1-6 g/day."
        }, 
        "brief_title": "BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "IgA Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Glomerulonephritis, IGA", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 - 65 years of age, inclusive\n\n          -  Biopsy-proven IgA nephropathy\n\n          -  Receiving stable, clinically-optimized ACEI and/or ARB\n\n          -  Proteinuria \u2265 1g/24hr but \u2264 6g/24hr at 2 consecutive time points\n\n        Exclusion Criteria:\n\n          -  Clinical or histologic evidence of non-IgA-related glomerulonephritis\n\n          -  IgA nephropathy with greater than 50% glomerulosclerosis or cortical scarring\n\n          -  Meets eGFR criteria\n\n          -  History of treatment with oral or parenteral corticosteroids within 3 months or\n             immunosuppressants within 6 months\n\n          -  Malignancy within past 5 years\n\n          -  Known to be positive for HIV and/or positive at the screening visit for hepatitis B,\n             or hepatitis C\n\n          -  Liver disease\n\n          -  Neutropenia\n\n          -  Active infection requiring hospitalization or treatment with parenteral antibiotics\n             within the past 60 days or history of repeated herpetic viral infections\n\n          -  History of active tuberculosis or a history of tuberculosis infection\n\n          -  Pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062684", 
            "org_study_id": "AN-IGN3321"
        }, 
        "intervention": [
            {
                "arm_group_label": "Blisibimod", 
                "intervention_name": "Blisibimod", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "IgAN", 
            "IgA Nephropathy", 
            "A-623", 
            "Blisibimod", 
            "Kidney Disease", 
            "Persistent proteinuria"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Investigator Site 101"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of", 
                        "zip": "301-721"
                    }, 
                    "name": "Investigator Site 303"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Investigator Site 301"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "137-701"
                    }, 
                    "name": "Investigator Site 302"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cheras", 
                        "country": "Malaysia", 
                        "zip": "56000"
                    }, 
                    "name": "Investigator Site 601"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kajang", 
                        "country": "Malaysia", 
                        "zip": "43000"
                    }, 
                    "name": "Investigator Site 603"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia", 
                        "zip": "59100"
                    }, 
                    "name": "Investigator Site 602"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cavite", 
                        "country": "Philippines"
                    }, 
                    "name": "Investigator Site 403"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Davao City", 
                        "country": "Philippines"
                    }, 
                    "name": "Investigator Site 406"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Makati City", 
                        "country": "Philippines"
                    }, 
                    "name": "Investigator Site 405"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quezon City", 
                        "country": "Philippines"
                    }, 
                    "name": "Investigator Site 404"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quezon City", 
                        "country": "Philippines", 
                        "zip": "1101"
                    }, 
                    "name": "Investigator Site 402"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quezon City", 
                        "country": "Philippines"
                    }, 
                    "name": "Investigator Site 401"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "308433"
                    }, 
                    "name": "Investigator Site 201"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "169608"
                    }, 
                    "name": "Investigator Site 202"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "100"
                    }, 
                    "name": "Investigator Site 702"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "100"
                    }, 
                    "name": "Investigator Site 703"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10400"
                    }, 
                    "name": "Investigator Site 502"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }, 
                    "name": "Investigator Site 503"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10330"
                    }, 
                    "name": "Investigator Site 504"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10400"
                    }, 
                    "name": "Investigator Site 505"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chang Mai", 
                        "country": "Thailand", 
                        "zip": "50200"
                    }, 
                    "name": "Investigator Site 501"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Hong Kong", 
                "Korea, Republic of", 
                "Malaysia", 
                "Philippines", 
                "Singapore", 
                "Taiwan", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy", 
        "overall_contact": {
            "email": "awinterhall@anthera.com", 
            "last_name": "Annie Winterhall", 
            "phone": "510-856-5600"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of subjects achieving reduction in proteinuria from baseline", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in serum immunoglobulins IgA, IgG and IgM", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Percent reduction from baseline in plasma cells and B-cell subsets", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Percent change from baseline in complement C3 and C4", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Proportion of subjects progressing to End Stage Renal Disease", 
                "safety_issue": "No", 
                "time_frame": "Approximately 104 weeks"
            }, 
            {
                "measure": "Proportion of subjects achieving reduction in proteinuria from baseline", 
                "safety_issue": "No", 
                "time_frame": "Approximately 104 weeks"
            }, 
            {
                "measure": "Numbers of subjects requiring the addition of corticosteroid or other therapy", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Anthera Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anthera Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}